Managed Care Industry Convenes in Washington, DC for AMCP Nexus 2025

Thousands of managed care pharmacy professionals from health plans, PBMs, pharmaceutical manufacturers, and other managed care organizations convened in National Harbor, MD, from Oct. 27-31 for AMCP Nexus 2025. Co-located at Nexus was our inaugural Pharmacy Policy Summit, which will continue to be held in the Washington, DC metropolitan area in years to come.

Attendees connected with peers from across the diverse roles of managed care, discussed the key trends impacting their work, and expanded their perspectives through industry-leading education sessions featuring resources from AMCP Learn, AMCP Foundation, the AMCP Research Institute (ARI), and the Biologics & Biosimilars Collective Intelligence Consortium (BBCIC). 

"Every single day, our members are trying to make things better for patients in a responsible way. Steps like relaxing or eliminating prior authorizations for certain chronic condition treatments strike the right balance between simplifying the experience for patients while still ensuring that prescriptions are used safely and appropriately."

- AMCP CEO, Susan Cantrell, MHL, RPh, CAE 

The event featured speakers from across all areas of managed care pharmacy, as well as an insightful outside perspective from former Speaker of the House Paul Ryan in a keynote address. Speaker Ryan has been closer than most to the processes behind the nation’s health care system, and his message was of the necessity for significant reform. “Our social contract is a healthy retirement security for all Americans and a safety net for the poor. Medicaid is a big part of the safety net. The challenge we have as a society is that we designed the social contract in the 20th century in a way that is proving fiscally unsustainable in the 21st century,” said Ryan.

📸 Take a look back at some moments from AMCP CEO Susan Cantrell's fireside chat with Speaker Paul Ryan at #AMCPNexus 2025 and the conversations it inspired. Thank you to our presenting sponsor @AstraZeneca. #WeAreAMCP #managedcare #healthpolicy @amcpceo pic.twitter.com/3tVdrQ16oW

— AMCP (@amcporg) October 29, 2025

HBCU Travel Award and Cathy A. Carroll Scholarship recipients were honored at receptions, and we announced our Student, Resident/Fellow, and Graduate Best Poster Award recipients. Learn more about all of this year’s outstanding winners shaping the present and future of managed care pharmacy here.

Attendees had the opportunity to network with dozens of exhibitors showcasing cutting-edge products aimed at enhancing patient outcomes, alongside more than 300 research posters highlighting the latest industry advancements. These were complemented by Spotlight Sessions, Satellite Symposia, Poster Tours, and our first ever real-world evidence arena offering valuable insights into emerging trends and clinical developments including artificial intelligence, precision medicine, and the evolving policy landscape at both state and federal levels. 

Just over two weeks out from Nexus 2025, we still feel the energy and enthusiasm from the AMCP members and stakeholders in attendance, excited to keep working on the issues on our agenda and eager to learn more about emerging trends just underway. Miss a session? They are now available on AMCP Learn. Below are our key takeaways:

1. Nearly 300 new medicines are expected by 2028, with ~100 orphan drugs; oncology & immunology will drive >50% of spending growth by 2028. 
2. There are >120 molecules in the obesity pipeline; employers report increased member utilization of obesity treatments as the #1 current trend, with ≥50% requiring weight management program participation and ~90% using PA. 
3. GLP1 market could exceed $100B by 2030 with ~30M U.S. users (~9% of population) under base assumptions; cases project up to 70M users by 2028 if indications expand. 
4. CMS’s CGT Access Model now includes 33 states + DC + PR, covering ~84% of Medicaid sickle cell disease lives. 
5. Only 36% of eligible advanced NSCLC patients ultimately receive biomarker-guided treatment due to losses across the testing-to-treatment pathway. 
6. Spending on genetic tests has nearly quadrupled since 2014; >60% of oncology approvals in past five years are precision therapies.
7. Global oncology spend hit $252B (2024) and is projected to reach $441B by 2029; median annual cost $411,855 for new agents launched in 2024. 
8. Proposed/active frameworks include 15% branded tariffs (EU/Japan deals) and country specific rates up to 50% (India) and 100% for certain branded meds under Section 232 proposals. 
9. Payers report 66% positive ROI on GenAI pilots, with practical wins including intelligent document processing for faxes/handwriting and PA pre-fill. 
10. Most CARTs are limited to ~150 FACT accredited centers; 85% report near full capacity; being >25 miles from a center reduces receipt of CART by 47%; median referral to the time of cell collection is 84 days.

AMCP extends our sincere thanks to the sponsors of Nexus 2025. Your partnership helped make this event possible and supports our ongoing efforts to advance the field of managed care pharmacy. We appreciate your continued commitment to the profession and to fostering meaningful engagement across the health care community.

Following the success of Nexus 2025, AMCP members and others working in managed care pharmacy are now looking forward towards AMCP Annual 2026, which will be held in Nashville, TN, Apr. 13–16, 2026.

Sponsorship and exhibiting opportunities are already available, and registration opens on Dec. 9, 2025, for AMCP members and Dec. 10, 2025, for the general public. Join AMCP to save up to $400 on conference registration and students can save more than $1,000 off the full, non-member registration!

View the Nexus Photo Gallery